Merck Completes Acquisition of Verona Pharma in $10B Deal

Merck announced on Tuesday it had completed the acquisition of Verona Pharma, a $10 billion deal that strengthens Merck’s cardio-pulmonary portfolio with the drug Ohtuvayre, a first-in-class treatment for chronic obstructive pulmonary disease (COPD). 

Verona Pharma is now a wholly owned subsidiary of Merck, and American Depositary Shares (ADS) of Verona Pharma will no longer be listed or traded on the Nasdaq Global Market. 

“The Verona Pharma acquisition strengthens and complements our portfolio of treatments for patients with cardio-pulmonary diseases to include Ohtuvayre, while delivering near and long-term growth as well as value for shareholders,” said Merk Chairman and CEO Robert M. Davis in a statement on Tuesday. 

Read more at NJBIA